Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain

INmune Bio Inc. (NASDAQ:INMB) stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45 million, as per data from Benzinga Pro. The company announced results from its Phase 2 MINDFuL trial evaluating XPro, a selective soluble TNF inhibitor, in…